Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Tcr2 Therapeutics Inc. (TCRR)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Tcr2 Therapeutics Inc. since year 2005.
Table 2 shows the detailed insider transactions of Tcr2 Therapeutics Inc. since 2005.
The reporting company's ticker symbol is TCRR. The reporting company's CIK number is 1750019.
The total value of stock buying since 2005 is $64,799,985.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-02-19||China Molybdenum (hong Kong) Co Ltd (10% Owner)||Buy||200,000||15.00||3,000,000|
|2019-02-19||F2 Capital I 2019, Llc (10% Owner)||Buy||666,667||15.00||10,000,005|
|2019-02-19||Mpm Sunstates Gp Managing Member Llc (10% Owner)||Buy||706,666||15.00||10,599,990|
|2019-02-19||Mpm Oncology Impact Management Gp Llc (10% Owner)||Buy||666,667||15.00||10,000,005|
|2019-02-19||Mpm Asset Management Llc (10% Owner)||Buy||706,666||15.00||10,599,990|
|2019-02-19||Gadicke Ansbert (Director)||Buy||1,373,333||15.00||20,599,995|
Insider trading activities including stock purchases, stock sales, and option exercises of TCRR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Tcr2 Therapeutics Inc. (symbol TCRR, CIK number 1750019) see the Securities and Exchange Commission (SEC) website.